For its fourth fiscal quarter (ending December 31), Integra LifeSciences Holdings Co (NASDAQ: IART) has reported a -61% decline in E.P.S. from $0.64 a year ago to $0.25 in the current quarter. This result fell short of the consensus estimate of $0.90 by $-0.65. For the latest four quarters through December 31, E.P.S. were $0.84 versus $2.18 for the same period a year ago — a decline of -61%.
Recent Price Action
Integra LifeSciences Holdings Co (NASDAQ: IART) stock suffered a major decline of -12.6% on 2/28/24. The shares closed at $38.67. Moreover, this decline was accompanied by exceptionally high trading volume at 455% of normal. The stock has performed in line with the market over the last nine months and has declined -14.4% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, IART is expected to continue to be an important Value Builder.
Integra LifeSciences Holdings has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Integra LifeSciences Holdings has a neutral Appreciation Score of 52 and a neutral Power Rating of 49, resulting in the Neutral Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment